JP2006512362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006512362A5 JP2006512362A5 JP2004561981A JP2004561981A JP2006512362A5 JP 2006512362 A5 JP2006512362 A5 JP 2006512362A5 JP 2004561981 A JP2004561981 A JP 2004561981A JP 2004561981 A JP2004561981 A JP 2004561981A JP 2006512362 A5 JP2006512362 A5 JP 2006512362A5
- Authority
- JP
- Japan
- Prior art keywords
- phenylthio
- ethoxy
- methyl
- composition
- indolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 23
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 4
- -1 nitro, hydroxy Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- OTLFMBASBKXJNW-UHFFFAOYSA-N 2-[3-[2-(4-chlorophenyl)ethoxy]phenyl]sulfanyl-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)SC1=CC=CC(OCCC=2C=CC(Cl)=CC=2)=C1 OTLFMBASBKXJNW-UHFFFAOYSA-N 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- GRHJZPROPPSAFT-UHFFFAOYSA-N methyl 2-[3-[2-(4-chlorophenyl)ethoxy]phenyl]sulfanyl-2-methylpropanoate Chemical compound COC(=O)C(C)(C)SC1=CC=CC(OCCC=2C=CC(Cl)=CC=2)=C1 GRHJZPROPPSAFT-UHFFFAOYSA-N 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- DWNAOGBFRUBOCO-UHFFFAOYSA-N 2-[3-(2-carbazol-9-ylethoxy)phenyl]sulfanyl-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)SC1=CC=CC(OCCN2C3=CC=CC=C3C3=CC=CC=C32)=C1 DWNAOGBFRUBOCO-UHFFFAOYSA-N 0.000 claims 2
- QHYKGIQDMPNJJI-UHFFFAOYSA-N 2-[4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]sulfanyl-2-methylpropanoic acid Chemical compound C1=CC(SC(C)(C)C(O)=O)=CC=C1OCCC1=CC=C(Cl)C=C1Cl QHYKGIQDMPNJJI-UHFFFAOYSA-N 0.000 claims 2
- KQOUPKWYTFDYKN-UHFFFAOYSA-N 2-[4-[2-(4-chlorophenyl)ethoxy]phenyl]sulfanyl-2-methylpropanoic acid Chemical compound C1=CC(SC(C)(C)C(O)=O)=CC=C1OCCC1=CC=C(Cl)C=C1 KQOUPKWYTFDYKN-UHFFFAOYSA-N 0.000 claims 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical group C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- QPYXUXMMGHQWFW-UHFFFAOYSA-N methyl 2-[3-(2-carbazol-9-ylethoxy)phenyl]sulfanyl-2-methylpropanoate Chemical compound COC(=O)C(C)(C)SC1=CC=CC(OCCN2C3=CC=CC=C3C3=CC=CC=C32)=C1 QPYXUXMMGHQWFW-UHFFFAOYSA-N 0.000 claims 2
- XLJXISQIZHFLMA-UHFFFAOYSA-N methyl 2-[3-(2-indol-1-ylethoxy)phenyl]sulfanyl-2-methylpropanoate Chemical compound COC(=O)C(C)(C)SC1=CC=CC(OCCN2C3=CC=CC=C3C=C2)=C1 XLJXISQIZHFLMA-UHFFFAOYSA-N 0.000 claims 2
- YMJGOAORYQMDJT-UHFFFAOYSA-N methyl 2-[3-[2-(2,4-dichlorophenyl)ethoxy]phenyl]sulfanyl-2-methylpropanoate Chemical compound COC(=O)C(C)(C)SC1=CC=CC(OCCC=2C(=CC(Cl)=CC=2)Cl)=C1 YMJGOAORYQMDJT-UHFFFAOYSA-N 0.000 claims 2
- SWZSLTMGUHIKSI-UHFFFAOYSA-N methyl 2-[4-[2-(2,4-dichlorophenyl)ethoxy]phenyl]sulfanyl-2-methylpropanoate Chemical compound C1=CC(SC(C)(C)C(=O)OC)=CC=C1OCCC1=CC=C(Cl)C=C1Cl SWZSLTMGUHIKSI-UHFFFAOYSA-N 0.000 claims 2
- HPDVBEOKTBFEAD-UHFFFAOYSA-N methyl 2-[4-[2-(4-chlorophenyl)ethoxy]phenyl]sulfanyl-2-methylpropanoate Chemical compound C1=CC(SC(C)(C)C(=O)OC)=CC=C1OCCC1=CC=C(Cl)C=C1 HPDVBEOKTBFEAD-UHFFFAOYSA-N 0.000 claims 2
- IXENVMWQFPRCCJ-UHFFFAOYSA-N methyl 2-methyl-2-[3-[[5-(4-nitrophenyl)furan-2-yl]methoxy]phenyl]sulfanylpropanoate Chemical compound COC(=O)C(C)(C)SC1=CC=CC(OCC=2OC(=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=C1 IXENVMWQFPRCCJ-UHFFFAOYSA-N 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000000681 2-(2-naphthyl)ethoxy group Chemical group [H]C1=C([H])C2=C(C([H])=C1[H])C([H])=C(C([H])=C2[H])C([H])([H])C([H])([H])O* 0.000 claims 1
- GVPODITZTGRXFG-UHFFFAOYSA-N 2-methyl-2-[3-[[5-(4-nitrophenyl)furan-2-yl]methoxy]phenyl]sulfanylpropanoic acid Chemical compound OC(=O)C(C)(C)SC1=CC=CC(OCC=2OC(=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=C1 GVPODITZTGRXFG-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000009862 primary prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000009863 secondary prevention Effects 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 208000032598 susceptibility microvascular complications of diabetes Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000629A ITRM20020629A1 (it) | 2002-12-19 | 2002-12-19 | Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante. |
| PCT/IT2003/000820 WO2004056355A1 (en) | 2002-12-19 | 2003-12-16 | USE OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXYCARBOXYLIC ACIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006512362A JP2006512362A (ja) | 2006-04-13 |
| JP2006512362A5 true JP2006512362A5 (https=) | 2007-02-08 |
Family
ID=32676886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004561981A Pending JP2006512362A (ja) | 2002-12-19 | 2003-12-16 | 血清グルコース低下および血清脂質低下活性を有するα−フェニルチオカルボン酸およびα−フェニルオキシカルボン酸の使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7375124B2 (https=) |
| EP (1) | EP1572180B1 (https=) |
| JP (1) | JP2006512362A (https=) |
| KR (1) | KR20050085222A (https=) |
| CN (1) | CN100393309C (https=) |
| AR (1) | AR042547A1 (https=) |
| AT (1) | ATE423558T1 (https=) |
| AU (1) | AU2003288546B8 (https=) |
| BR (1) | BR0317359A (https=) |
| CA (1) | CA2506627A1 (https=) |
| DE (1) | DE60326382D1 (https=) |
| DK (1) | DK1572180T3 (https=) |
| ES (1) | ES2321708T3 (https=) |
| IT (1) | ITRM20020629A1 (https=) |
| MX (1) | MXPA05005848A (https=) |
| PL (1) | PL378414A1 (https=) |
| PT (1) | PT1572180E (https=) |
| SI (1) | SI1572180T1 (https=) |
| TW (1) | TWI308564B (https=) |
| WO (1) | WO2004056355A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006045010A2 (en) * | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| WO2008092231A1 (en) | 2007-02-01 | 2008-08-07 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
| MX2011002448A (es) * | 2008-09-05 | 2011-05-25 | Acucela Inc | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos. |
| AU2010204106B2 (en) | 2009-01-08 | 2014-05-08 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
| NZ755378A (en) | 2009-03-18 | 2022-07-29 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
| KR20190091564A (ko) | 2009-04-22 | 2019-08-06 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| RU2640115C2 (ru) | 2011-11-01 | 2017-12-26 | Ресверлоджикс Корп. | Фармацевтические композиции замещенных хиназолинонов |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
| CN114901641B (zh) * | 2020-02-28 | 2025-06-17 | 四川科伦博泰生物医药股份有限公司 | 芳香族化合物及其药物组合物和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB860303A (en) * | 1958-06-20 | 1961-02-01 | Ici Ltd | Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª |
| GB1121722A (en) * | 1966-03-31 | 1968-07-31 | Ici Ltd | New carboxylic acid derivatives |
| GB1422679A (en) * | 1972-11-16 | 1976-01-28 | Funai Pharmaceutical Ind Ltd | Substituted phenoxy-a-methylpropionic acid derivatives and a process for producing the same |
| FR2285867A1 (fr) * | 1974-09-30 | 1976-04-23 | Lafon Labor | Derives du diphenylsulfoxyde |
| ITRM20020014A1 (it) * | 2002-01-15 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del |
-
2002
- 2002-12-19 IT IT000629A patent/ITRM20020629A1/it unknown
-
2003
- 2003-12-16 AU AU2003288546A patent/AU2003288546B8/en not_active Ceased
- 2003-12-16 DE DE60326382T patent/DE60326382D1/de not_active Expired - Lifetime
- 2003-12-16 US US10/539,833 patent/US7375124B2/en not_active Expired - Fee Related
- 2003-12-16 PL PL378414A patent/PL378414A1/pl unknown
- 2003-12-16 CA CA002506627A patent/CA2506627A1/en not_active Abandoned
- 2003-12-16 DK DK03780669T patent/DK1572180T3/da active
- 2003-12-16 SI SI200331556T patent/SI1572180T1/sl unknown
- 2003-12-16 KR KR1020057009770A patent/KR20050085222A/ko not_active Ceased
- 2003-12-16 JP JP2004561981A patent/JP2006512362A/ja active Pending
- 2003-12-16 AT AT03780669T patent/ATE423558T1/de not_active IP Right Cessation
- 2003-12-16 CN CNB200380106699XA patent/CN100393309C/zh not_active Expired - Fee Related
- 2003-12-16 MX MXPA05005848A patent/MXPA05005848A/es active IP Right Grant
- 2003-12-16 BR BR0317359-3A patent/BR0317359A/pt not_active IP Right Cessation
- 2003-12-16 WO PCT/IT2003/000820 patent/WO2004056355A1/en not_active Ceased
- 2003-12-16 PT PT03780669T patent/PT1572180E/pt unknown
- 2003-12-16 EP EP03780669A patent/EP1572180B1/en not_active Expired - Lifetime
- 2003-12-16 ES ES03780669T patent/ES2321708T3/es not_active Expired - Lifetime
- 2003-12-18 TW TW092136024A patent/TWI308564B/zh not_active IP Right Cessation
- 2003-12-19 AR ARP030104731A patent/AR042547A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006512362A5 (https=) | ||
| RU2419624C2 (ru) | Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| RU2312106C2 (ru) | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar | |
| JP2004520292A5 (https=) | ||
| JP2009528375A5 (https=) | ||
| WO2006022428A1 (ja) | 糖尿病治療剤 | |
| RU2008106058A (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
| JP2007511485A5 (https=) | ||
| EP1423145A1 (fr) | Compositions pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau | |
| JP2005112864A5 (https=) | ||
| CA2401502A1 (en) | Carboxylic acid derivatives as ip antagonists | |
| CN102459185A (zh) | 新型甲状腺激素β受体激动剂 | |
| JP2009537559A5 (https=) | ||
| RU2005128501A (ru) | Соединение для лечения метаболических расстройств | |
| JP2011500679A5 (https=) | ||
| EP1696909A1 (en) | Benzothiazole derivatives for the treatment of diabetes | |
| JP2009528275A5 (https=) | ||
| CA2521621A1 (en) | Compounds for the treatment of metabolic disorders | |
| HU230609B1 (hu) | Hipolipidémiás és hipokoleszterinémiás hatású szubsztituált pirrolszármazékok, azokat tartalmazó gyógyszerkészítmények, eljárás előállításukra, köztitermékek és alkalmazásuk | |
| JP2006524252A5 (https=) | ||
| JP2005526696A5 (https=) | ||
| JP2005514452A5 (https=) | ||
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2005532331A5 (https=) | ||
| JPWO2006057152A1 (ja) | タンパク質分解酵素阻害化合物からなる糖尿病治療剤 |